DIRS.INFO top alerts submit data jurnalism about API
login
Top related persons:
Emily Field - 4 it's - 2 Eli Lilly - 1 Emily - 1 Joakim Tabet - 1 Kepler - 1 Tabet - 1 Vincent Denoiseux - 1
Top related locs:
Europe Danish Novo U.S Canadian Germany Denmark Norway
Top related orgs:
Barclays - 4 Novo Nordisk - 2 CNBC - 2 pharma - 2 European Pharmaceuticals - 1 Healthcare UCITS - 1 London Stock Exchange - 1 TSX - 1

Search resuls for: "European Pharmaceuticals"


6 mentions found


☆ Novo Nordisk, Eli Lilly have strong first-mover advantage in weight loss drug market, analyst says
  + stars: | 2024-07-18 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailNovo Nordisk, Eli Lilly have strong first-mover advantage in weight loss drug market, analyst saysEmily Field, head of European pharmaceuticals research at Barclays, says it's too early to say what the competitive landscape will look like in five years for the weight loss drug market, as many trials are still in an early stage.
Persons: Eli Lilly, Emily Field, it's Organizations: Novo Nordisk, Barclays
☆ Obesity drugs will be the largest pharamaceutical class ever, says Emily Field
  + stars: | 2024-02-29 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity drugs will be the largest pharamaceutical class ever, says Emily FieldEmily Field, Director and Lead Analyst of European Pharmaceuticals at Barclays, discusses weight-loss and GLP-1 drugs.
Persons: Emily, Emily Field Organizations: European Pharmaceuticals, Barclays
☆ These are the only 2 ETFs that made money every year for the past decade
  + stars: | 2024-02-19 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +4 min
Two funds investing in defensive stocks are the only exchange-traded funds in the world that had a positive return every year over the past decade, CNBC Pro research has found. The two funds stood out among 8,300 equity ETFs worldwide screened by CNBC Pro using FactSet data. Over that period, the ETF more than doubled investors' money, with a cumulative total price gain of 118%. While the MSCI Healthcare index, valued in euros, dipped slightly into negative territory in 2016, 2020 and 2022, the Amundi ETF's total returns have remained positive because of the weakness in the pound sterling. However, Tabet also pointed out that the health-care sector, especially European pharma, tends to underperform in election years.
Persons: Joakim Tabet, Kepler, Tabet, Vincent Denoiseux, David Evans, Evans, Kepler Cheuvreux Organizations: CNBC, Healthcare UCITS, London Stock Exchange, TSX, Consumer Staples, CNBC Pro, Outlook Novo Nordisk, Novo Nordisk's, pharma, European pharma Locations: Canadian, Europe, Danish, Novo, U.S
☆ Obesity 'bolt-ons' likely to spur pharma M&A in 2024: Analyst
  + stars: | 2024-02-02 | by ( ) www.cnbc.com   time to read: 1 min
Share Share Article via Facebook Share Article via Twitter Share Article via LinkedIn Share Article via EmailObesity 'bolt-ons' likely to spur pharma M&A in 2024: AnalystEmily Field, director and head of European pharmaceuticals equity research at Barclays, says the industry is likely to see an uptick in mergers and acquisitions in 2024, especially with smaller deals in the obesity drugs space.
Persons: Emily Field Organizations: pharma, Barclays
☆ Weight loss drug Wegovy is from Europe — but users in the region face a long and costly wait
  + stars: | 2023-07-26 | by ( Karen Gilchrist | ) www.cnbc.com   time to read: +3 min
Packages of the weight-loss drug Wegovy from the pharmaceutical company Novo Nordisk lie on the sales counter in a Danish pharmacy. Still, it's seen as too expensive for many public health systems in Europe. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe. Eli Lily , whose diabetes drug Mounjaro can also be used for weight loss, has also faced supply gluts. They're obviously in a capacity constrained environment and we don't know how much they're willing to allocate to Europe," Field said.
Persons: Stefan Trumpf, it's, Emily Field, Wegovy's, Eli Lily Organizations: Novo Nordisk, Getty, CNBC, Denmark — Novo, Barclays, BMI, German Obesity Society, Novo Nordisk — Locations: Danish, Germany, Europe, Denmark, Norway, Novo, U.S
☆ This weight-loss drug maker's stock is up 20% this year — and Barclays sees it going higher
  + stars: | 2023-04-28 | by ( Ganesh Rao | ) www.cnbc.com   time to read: +3 min
Wegovy catapulted into the spotlight thanks to its success in weight loss and the endorsement by celebrities and social media influencers, including Tesla CEO Elon Musk. However, some investors are concerned that Novo's stock has already factored in this growth potential, as its shares have risen by 137% since the U.S. Food and Drug Administration approved the drug in June 2021. Novo's shares are also traded in New York Stock, London , and Frankfurt. NVO 5Y mountain According to Barclays' Field, the market for obesity treatment drugs could be worth as much as $200 billion within the next decade. "So does the weight loss that comes with taking Wegovy prevent you from having a heart attack or a stroke among those that have a higher risk?
0 next >>
Total: 6